New hope for slowing kidney damage in patients who Can't take standard drugs
NCT ID NCT07181135
Summary
This study is testing whether a daily pill called finerenone can help slow the progression of chronic kidney disease in adults who are not taking a common class of kidney-protective drugs (RAS inhibitors). About 180 participants will be randomly assigned to take either finerenone or a placebo (inactive pill) for six months. The main goal is to see if finerenone reduces the amount of protein in the urine, which is a key sign of kidney damage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clínica Universidad de Navarra
Madrid, Spain
-
Clínica Universidad de Navarra
Pamplona, Spain
-
Hospital Clinico Universitario de Valencia
Valencia, Spain
-
Hospital Universitari Germans Trias i Pujol
Barcelona, Spain
-
Hospital Universitario Dr Peset
Valencia, Spain
-
Hospital Universitario Puerta de Hierro
Madrid, Spain
-
Hospital Universitario de La Princesa
Madrid, Spain
-
Vall d'Hebron University Hospital
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.